Download PDF
Thromb Haemost 1998; 80(06): 936-941
DOI: 10.1055/s-0037-1615392
Letters to the Editor
Schattauer GmbH

Inhibition of Lupus Anticoagulant Activity by Hexagonal Phase Phosphatidylethanolamine in the Presence of Prothrombin

Joyce Rauch
1   Divisions of Rheumatology
,
Marion Tannenbaum
1   Divisions of Rheumatology
,
Carolyn Neville
1   Divisions of Rheumatology
2   Clinical Epidemiology, Department of Medicine, The Montreal General Hospital Research Institute, McGill University, Montreal, Quebec, Canada
,
Paul R. Fortin
1   Divisions of Rheumatology
2   Clinical Epidemiology, Department of Medicine, The Montreal General Hospital Research Institute, McGill University, Montreal, Quebec, Canada
› Author Affiliations
Further Information

Publication History

Received 06 April 1998

Accepted after resubmission 14 August 1998

Publication Date:
07 December 2017 (online)

    Permissions and Reprints

Summary

We have previously demonstrated that lupus anticoagulant antibodies from patients with systemic lupus erythematosus (SLE) specifically recognize hexagonal (II) phase phosphatidylethanolamine (PE), but not bilayer PE (Thromb Haemost 1989; 62: 892). In those studies, the involvement of proteins in this recognition was not evaluated. To address this issue, we have isolated IgG lupus anticoagulant antibodies from the plasma of SLE patients and evaluated the inhibition of lupus anticoagulant activity by hexagonal (II) phase PE in the presence and absence of purified plasma proteins. All six of the IgG lupus anticoagulant antibodies tested were inhibited by hexagonal (II) phase PE in the presence, but not the absence, of human prothrombin. In contrast, little or no inhibition was observed with prothrombin alone or with PE in combination with either β2-glycoprotein I or annexin V. These data indicate that, for certain lupus anticoagulant antibodies, inhibition by hexagonal (II) phase PE is dependent on prothrombin, suggesting that these antibodies recognize a complex of PE and prothrombin.

 

  • References

  • 1 Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other “antiphospholipid” antibodies. Blood 1994; 84: 2854-67.
    PubMedGoogle Scholar
  • 2 Rauch J, Janoff AS. Antibodies against phospholipids other than cardiolipin: potential roles for both phospholipid and protein. Lupus 1996; 5: 498-502.
    CrossrefPubMedGoogle Scholar
  • 3 Loeliger A. Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus. Thromb Diath Haemorrh 1959; 3: 237-56.
    PubMedGoogle Scholar
  • 4 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 1993; 81: 2618-25.
    PubMedGoogle Scholar
  • 6 Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 1984; 64: 807-16.
    PubMedGoogle Scholar
  • 7 Fleck RA, Rapaport SI, Rao LVM. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-9.
    PubMedGoogle Scholar
  • 8 Permpikul P, Rao LVM, Rapaport SI. Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83: 2878-92.
    PubMedGoogle Scholar
  • 9 Rao LVM, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996; 88: 4173-82.
    PubMedGoogle Scholar
  • 10 Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997; 77: 486-91.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 1989; 62: 892-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
    CrossrefPubMedGoogle Scholar
  • 13 Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 1996; 88: 1873-80.
    PubMedGoogle Scholar
  • 14 Rauch J, Tannenbaum M, Tannenbaum H, Ramelson H, Cullis PR, Tilcock CPS, Hope MJ, Janoff AS. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 1986; 261: 9672-7.
    PubMedGoogle Scholar
  • 15 Price BE, Rauch J, Shia MA, Walsh MT, Lieberthal W, Gilligan HM, O’Laughlin T, Koh JS, Levine JS. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β2-glycoprotein I-dependent manner. J Immunol 1996; 157: 2201-8.
    PubMedGoogle Scholar
  • 16 Puurunen M, Vaarala O, Julkunen H, Aho K, Palosuo T. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996; 80: 16-22.
    CrossrefPubMedGoogle Scholar
  • 17 Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Wu JR, Lentz BR. Phospholipid-specific conformational changes in human prothrombin upon binding to procoagulant acidic lipid membranes. Thromb Haemost 1994; 71: 596-604.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Galli M, Bevers EM. Inhibition of phospholipid-dependent coagulation reactions by “antiphospholipid antibodies”: possible modes of action. Lupus 1994; 3: 223-8.
    CrossrefPubMedGoogle Scholar
  • 20 Zwaal RFA. Membrane and lipid involvement in blood coagulation. Biochim Biophys Acta 1978; 515: 163-205.
    CrossrefPubMedGoogle Scholar
  • 21 Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
    PubMedGoogle Scholar
  • 22 van Rijn JLML, Govers-Riemslag JWP, Zwaal RFA, Rosing J. Kinetic studies of prothrombin activation: effect of factor Va and phospholipids on the formation of the enzyme-substrate complex. Biochemistry 1984; 23: 4557-64.
    CrossrefPubMedGoogle Scholar
  • 23 Jones ME, Lentz BR, Dombrose FA, Sanberg H. Comparison of the abilities of synthetic and platelet-derived membranes to enhance thrombin formation. Thromb Res 1985; 39: 711-24.
    CrossrefPubMedGoogle Scholar
  • 24 Papahadjopoulos D, Hanahan DJ. Observation on the interaction of phospholipids and certain clotting factors in prothrombin activator formation. Biochem Biophys Acta 1964; 90: 436-9.
    CrossrefPubMedGoogle Scholar
  • 25 Esmon CT, Owen WG, Jackson CM. The conversion of prothrombin to thrombin: V. The activation of prothrombin by factor Xa in the presence of phospholipid. J Biol Chem 1974; 249: 7798-807.
    PubMedGoogle Scholar
  • 26 Gerads I, Govers-Riemslag JWP, Tans G, Zwaal RFA, Rosing J. Prothrombin activation on membranes with anionic lipids containing phosphate, sulfate, and/or carboxyl groups. Biochemistry 1990; 29: 7967-74.
    CrossrefPubMedGoogle Scholar
  • 27 Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-9.
    PubMedGoogle Scholar
  • 28 Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-16.
    CrossrefPubMedGoogle Scholar
  • 29 Karmochkine M, Cacoub P, Piette JC, Godeau P, Boffa MC. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheumatol 1992; 10: 603-5.
    PubMedGoogle Scholar
  • 30 Staub HL, Harris EN, Khamashta MA, Savidge G, Chahade WH, Hughes GRV. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis 1989; 48: 166-9.
    CrossrefPubMedGoogle Scholar
  • 31 Karmochkine M, Berard M, Piette JC, Cacoub P, Aillaud MF, Harlé JR, Godeau P, Boffa MC. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus. Lupus 1993; 2: 157-60.
    CrossrefPubMedGoogle Scholar
  • 32 Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995; 86: 3083-9.
    PubMedGoogle Scholar
  • 33 Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996; 76: 354-60.
    Article in Thieme ConnectPubMedGoogle Scholar